NCT06197763View on ClinicalTrials.gov

Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

May 1, 2026

Conditions
Fontan Circulation
Interventions
DRUG

Colesevelam

625 mg tablets - 3 tables twice per day of Colesevelam or placebo for 6 weeks (crossover), interspersed by 8 week of washout time.

OTHER

Control Arm

No Treatment: baseline assessment only

All Listed Sponsors
lead

St. Boniface Hospital

OTHER

NCT06197763 - Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation. | Biotech Hunter | Biotech Hunter